Literature DB >> 28275577

Molecular Targeted Agents for Hepatocellular Carcinoma: Current Status and Future Perspectives.

M Kudo1.   

Abstract

Entities:  

Year:  2016        PMID： 28275577      PMCID： PMC5340214          DOI： 10.1159/000452138

Source DB:  PubMed          Journal:  Liver Cancer        ISSN： 1664-5553            Impact factor:   11.740


× No keyword cloud information.
  17 in total

1.  Regorafenib as Second-Line Systemic Therapy May Change the Treatment Strategy and Management Paradigm for Hepatocellular Carcinoma.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2016-09-14       Impact factor: 11.740

Review 2.  Rethinking future development of molecular therapies in hepatocellular carcinoma: a bottom-up approach.

Authors:  Augusto Villanueva
Journal:  J Hepatol       Date:  2013-03-30       Impact factor: 25.083

3.  Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma.

Authors:  Masatoshi Kudo; Kazuho Imanaka; Nobuyuki Chida; Kohei Nakachi; Won-Young Tak; Tadatoshi Takayama; Jung-Hwan Yoon; Takeshi Hori; Hiromitsu Kumada; Norio Hayashi; Shuichi Kaneko; Hirohito Tsubouchi; Dong Jin Suh; Junji Furuse; Takuji Okusaka; Katsuaki Tanaka; Osamu Matsui; Michihiko Wada; Iku Yamaguchi; Toshio Ohya; Gerold Meinhardt; Kiwamu Okita
Journal:  Eur J Cancer       Date:  2011-09       Impact factor: 9.162

4.  Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.

Authors:  Andrew X Zhu; Joon Oh Park; Baek-Yeol Ryoo; Chia-Jui Yen; Ronnie Poon; Davide Pastorelli; Jean-Frederic Blanc; Hyun Cheol Chung; Ari D Baron; Tulio Eduardo Flesch Pfiffer; Takuji Okusaka; Katerina Kubackova; Jorg Trojan; Javier Sastre; Ian Chau; Shao-Chun Chang; Paolo B Abada; Ling Yang; Jonathan D Schwartz; Masatoshi Kudo
Journal:  Lancet Oncol       Date:  2015-06-18       Impact factor: 41.316

5.  Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial.

Authors:  Andrew X Zhu; Masatoshi Kudo; Eric Assenat; Stéphane Cattan; Yoon-Koo Kang; Ho Yeong Lim; Ronnie T P Poon; Jean-Frederic Blanc; Arndt Vogel; Chao-Long Chen; Etienne Dorval; Markus Peck-Radosavljevic; Armando Santoro; Bruno Daniele; Junji Furuse; Annette Jappe; Kevin Perraud; Oezlem Anak; Dalila B Sellami; Li-Tzong Chen
Journal:  JAMA       Date:  2014-07-02       Impact factor: 56.272

6.  Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study.

Authors:  Josep M Llovet; Thomas Decaens; Jean-Luc Raoul; Eveline Boucher; Masatoshi Kudo; Charissa Chang; Yoon-Koo Kang; Eric Assenat; Ho-Yeong Lim; Valerie Boige; Philippe Mathurin; Laetitia Fartoux; Deng-Yn Lin; Jordi Bruix; Ronnie T Poon; Morris Sherman; Jean-Frédéric Blanc; Richard S Finn; Won-Young Tak; Yee Chao; Rana Ezzeddine; David Liu; Ian Walters; Joong-Won Park
Journal:  J Clin Oncol       Date:  2013-08-26       Impact factor: 44.544

7.  Sorafenib in advanced hepatocellular carcinoma.

Authors:  Josep M Llovet; Sergio Ricci; Vincenzo Mazzaferro; Philip Hilgard; Edward Gane; Jean-Frédéric Blanc; Andre Cosme de Oliveira; Armando Santoro; Jean-Luc Raoul; Alejandro Forner; Myron Schwartz; Camillo Porta; Stefan Zeuzem; Luigi Bolondi; Tim F Greten; Peter R Galle; Jean-François Seitz; Ivan Borbath; Dieter Häussinger; Tom Giannaris; Minghua Shan; Marius Moscovici; Dimitris Voliotis; Jordi Bruix
Journal:  N Engl J Med       Date:  2008-07-24       Impact factor: 91.245

8.  Post-progression survival and progression-free survival in patients with advanced hepatocellular carcinoma treated by sorafenib.

Authors:  Takeshi Terashima; Tatsuya Yamashita; Noboru Takata; Hidetoshi Nakagawa; Tadashi Toyama; Kuniaki Arai; Kazuya Kitamura; Taro Yamashita; Yoshio Sakai; Eishiro Mizukoshi; Masao Honda; Shuichi Kaneko
Journal:  Hepatol Res       Date:  2015-11-02       Impact factor: 4.288

9.  Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial.

Authors:  Ann-Lii Cheng; Yoon-Koo Kang; Deng-Yn Lin; Joong-Won Park; Masatoshi Kudo; Shukui Qin; Hyun-Cheol Chung; Xiangqun Song; Jianming Xu; Guido Poggi; Masao Omata; Susan Pitman Lowenthal; Silvana Lanzalone; Liqiang Yang; Maria Jose Lechuga; Eric Raymond
Journal:  J Clin Oncol       Date:  2013-09-30       Impact factor: 44.544

10.  Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study.

Authors:  Armando Santoro; Lorenza Rimassa; Ivan Borbath; Bruno Daniele; Stefania Salvagni; Jean Luc Van Laethem; Hans Van Vlierberghe; Jörg Trojan; Frank T Kolligs; Alan Weiss; Steven Miles; Antonio Gasbarrini; Monica Lencioni; Luca Cicalese; Morris Sherman; Cesare Gridelli; Peter Buggisch; Guido Gerken; Roland M Schmid; Corrado Boni; Nicola Personeni; Ziad Hassoun; Giovanni Abbadessa; Brian Schwartz; Reinhard Von Roemeling; Maria E Lamar; Yinpu Chen; Camillo Porta
Journal:  Lancet Oncol       Date:  2012-11-20       Impact factor: 41.316
View more
  14 in total

1.  Pembrolizumab for the Treatment of Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-04-29       Impact factor: 11.740

2.  Cabozantinib as a Second-Line Agent in Advanced Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-04-17       Impact factor: 11.740

3.  Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-08-23       Impact factor: 11.740

4.  Lenvatinib in Advanced Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2017-08-29       Impact factor: 11.740

5.  Combination Cancer Immunotherapy in Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-01-31       Impact factor: 11.740

6.  Lenvatinib May Drastically Change the Treatment Landscape of Hepatocellular Carcinoma.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-02-15       Impact factor: 11.740

7.  Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-07-09       Impact factor: 11.740

8.  Scientific Rationale for Combination Immunotherapy of Hepatocellular Carcinoma with Anti-PD-1/PD-L1 and Anti-CTLA-4 Antibodies.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2019-09-27       Impact factor: 11.740

Review 9.  Novel antigens for targeted radioimmunotherapy in hepatocellular carcinoma.

Authors:  Mahsa Pourhamzeh; Samieh Asadian; Hamed Mirzaei; Azita Minaei; Elahe Shahriari; Anastasia Shpichka; Hamidreza Aboulkheyr Es; Peter Timashev; Moustapha Hassan; Massoud Vosough
Journal:  Mol Cell Biochem       Date:  2022-06-16       Impact factor: 3.396

10.  Efficacy and Safety of Systemic Therapies for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis of Phase III Trials.

Authors:  Alessandro Cucchetti; Fabio Piscaglia; Antonio Daniele Pinna; Benjamin Djulbegovic; Federico Mazzotti; Luigi Bolondi
Journal:  Liver Cancer       Date:  2017-10-19       Impact factor: 11.740
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.